Multi-modality radiomics nomogram based on DCE-MRI and ultrasound images for benign and malignant breast lesion classification

ObjectiveTo develop a multi-modality radiomics nomogram based on DCE-MRI, B-mode ultrasound (BMUS) and strain elastography (SE) images for classifying benign and malignant breast lesions. Material and MethodsIn this retrospective study, 345 breast lesions from 305 patients who underwent DCE-MRI, BMUS and SE examinations were randomly divided into training (n = 241) and testing (n = 104) datasets. Radiomics features were extracted from manually contoured images. The inter-class correlation coefficient (ICC), Mann-Whitney U test and the least absolute shrinkage and selection operator (LASSO) regression were applied for feature selection and radiomics signature building. Multivariable logistic regression was used to develop a radiomics nomogram incorporating radiomics signature and clinical factors. The performance of the radiomics nomogram was evaluated by its discrimination, calibration, and clinical usefulness and was compared with BI-RADS classification evaluated by a senior breast radiologist. ResultsThe All-Combination radiomics signature derived from the combination of DCE-MRI, BMUS and SE images showed better diagnostic performance than signatures derived from single modality alone, with area under the curves (AUCs) of 0.953 and 0.941 in training and testing datasets, respectively. The multi-modality radiomics nomogram incorporating the All-Combination radiomics signature and age showed excellent discrimination with the highest AUCs of 0.964 and 0.951 in two datasets, respectively, which outperformed all single modality radiomics signatures and BI-RADS classification. Furthermore, the specificity of radiomics nomogram was significantly higher than BI-RADS classification (both p < 0.04) with the same sensitivity in both datasets. ConclusionThe proposed multi-modality radiomics nomogram based on DCE-MRI and ultrasound images has the potential to serve as a non-invasive tool for classifying benign and malignant breast lesions and reduce unnecessary biopsy.